ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.

ALACHUA, Fla. – June 25, 2020 – Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract to advance development of a cocktail of anti-botulinum neurotoxin monoclonal antibodies (mAb) by the Department of Defense (DOD) through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The contract ceiling value is $42.6 million.

Ology and Just - Evotech Collaborate to Develop Antibodies Against Coronavirus Partnership is part of a contract awarded to Ology Bioservices by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention of infection with Sars-CoV-2 Just – Evotec Biologics to supply antibody screening and analytical characterization of anti-covid-19 antibodies

The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices Inc...